A new post-hoc analysis set for presentation at the European Congress on Obesity (ECO 2026) will evaluate orforglipron, an oral GLP-1 receptor agonist, in adults aged 65 and older with obesity. The analysis examines efficacy and safety across older adults regardless of type 2 diabetes status, comparing outcomes in groups with and without T2D. The work is expected to add decision-relevant evidence for an age group that often responds differently to metabolic therapies and may have different tolerability considerations. For prescribing, route matters too: orforglipron is positioned as an oral alternative within the GLP-1 class. The presentation is scheduled for Istanbul during ECO 2026, where it will contribute to evolving data packages for obesity management in older patients.